Why the study?
The efficacy and safety of current antithrombotic strategies, the role of functional assessment and intravascular imaging, and the impact of comorbidity on PCI outcomes in patients with atrial fibrillation require comprehensive evaluation.
A narrative review highlighting that dual antithrombotic therapy (DOAC plus clopidogrel) and the use of functional assessment and intravascular imaging improve outcomes and reduce bleeding risks in patients with atrial fibrillation undergoing PCI.
Objective: To study the efficacy and safety of current antithrombotic strategies, the role of functional assessment and intravascular imaging, and the impact of comorbidity on the outcomes of percutaneous coronary intervention in patients with atrial fibrillation. Materials and Methods: This review article analyzes the results of randomized clinical trials, systematic literature reviews, and meta-analyses covering randomized and observational studies from 2021 to 2025. Results: Approximately 20-30% of patients with atrial fibrillation will require percutaneous coronary intervention (PCI) during their lifetime. Of these, approximately 12% already have concomitant atrial fibrillation, which requires a careful balance between antithrombotic and anticoagulant therapy.
No takes yet. Share an insight, caveat, or question.
Faizulloev et al. (2026) conducted a review in Atrial fibrillation and coronary artery disease requiring percutaneous coronary intervention. Percutaneous coronary intervention and dual antithrombotic therapy vs. Triple antithrombotic therapy (historical) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: